Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Health

FDA

Genetics

Clinical Trials

Rebyota

More Like This

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement

Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

The Biocodex Group Strengthens Its Position in Microbiota, With the Signature of a Licensing Agreement With My Health, a Belgian Biotech Company Specializing in Microbiota Solutions

Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection